NASDAQ:KDNY Chinook Therapeutics (KDNY) Stock Price, News & Analysis → Will this AI Micro-Cap be Bigger than NVIDIA? (From Behind the Markets) (Ad) Free KDNY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$40.39▼$40.3950-Day Range$38.66▼$40.3952-Week Range$18.34▼$40.51VolumeN/AAverage Volume1.19 million shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice Target$41.00 Stock AnalysisStock Analysis Get Chinook Therapeutics alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Chinook Therapeutics Stock (NASDAQ:KDNY)Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Read More Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> KDNY Stock News HeadlinesMay 21, 2024 | yahoo.comChinook, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 21, 2024 | finance.yahoo.comThree Finalists Announced for the 2024 Bloom Burton AwardNovember 1, 2023 | usnews.comChinook ElementaryAugust 8, 2023 | msn.comWedbush Downgrades Chinook Therapeutics (KDNY)August 2, 2023 | uk.finance.yahoo.comChinook Therapeutics, Inc. (KDNY)August 1, 2023 | markets.businessinsider.comExpert Ratings for Chinook TherapeuticsAugust 1, 2023 | msn.comWells Fargo Downgrades Chinook Therapeutics (KDNY)July 25, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOTJuly 16, 2023 | fool.comChinook Therapeutics (NASDAQ: KDNY)June 21, 2023 | seekingalpha.comChinook: Surprising Acquisition By Novartis, Deal Should Go ThroughJune 17, 2023 | finance.yahoo.comChinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressJune 16, 2023 | benzinga.comMoore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law FirmJune 14, 2023 | businesswire.comCHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook ...June 13, 2023 | barrons.comKDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to ShareholdersJune 13, 2023 | reuters.comNovartis buys Chinook for $3.5 bln in race to treat rare kidney diseaseJune 13, 2023 | markets.businessinsider.comWhy Are Chinook Therapeutics Shares Trading Higher TodayJune 12, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Chinook TherapeuticsJune 12, 2023 | finance.yahoo.comChinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) CongressJune 12, 2023 | seekingalpha.comNovartis Buys Chinook: M&A To Drive Future GrowthJune 12, 2023 | investorplace.comWhy Is Chinook Therapeutics (KDNY) Stock Up 58% Today?June 8, 2023 | markets.businessinsider.comChinook Shareholder Action ReminderMay 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Chinook Therapeutics (KDNY) and Zoetis (ZTS)May 21, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNYMay 21, 2023 | benzinga.comChinook Shareholder NoticeMay 19, 2023 | seekingalpha.comChinook Therapeutics: Travere's Pain Is Chinook's GainSee More Headlines Receive KDNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KDNY CUSIPN/A CIK1435049 Webchinooktx.com Phone(206) 485-7241FaxN/AEmployees214Year FoundedN/APrice Target and Rating Average Stock Price Target$41.00 High Stock Price Target$42.00 Low Stock Price Target$40.00 Potential Upside/Downside+1.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,870,000.00 Net Margins-4,199.93% Pretax Margin-4,115.56% Return on Equity-58.28% Return on Assets-44.72% Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual Sales$6.13 million Price / Sales473.15 Cash FlowN/A Price / Cash FlowN/A Book Value$6.91 per share Price / Book5.85Miscellaneous Outstanding Shares71,810,000Free Float59,749,000Market Cap$2.90 billion OptionableOptionable Beta0.34 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Eric L. Dobmeier J.D. (Age 54)Pres, CEO & Director Comp: $972.19kMr. Tom Frohlich (Age 47)Chief Operating Officer Comp: $627.44kMr. Andrew James King D.V.M. (Age 43)Ph.D., Chief Scientific Officer Comp: $651.48kMr. Eric H. Bjerkholt M.B.A. (Age 63)Chief Financial Officer Ms. Sukhi ThethySr. VP of Fin. & AccountingMs. Noopur Batsha LiffickSr. VP of Investor Relations & Corp. CommunicationsMr. Kirk D. Schumacher J.D.Sr. VP & Gen. CounselMs. Jodi JamiesonSr. VP of HRDr. Alan Glicklich M.D. (Age 60)Exec. Officer Ms. Delphine Imbert Ph.D.Sr. VP of CMC & Technical OperationsMore ExecutivesKey Competitors89bioNASDAQ:ETNBLianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXMPolarityTENASDAQ:PTEIQ9 Meters BiopharmaNASDAQ:NMTRView All CompetitorsInsidersAndrew James KingSold 1,168 sharesTotal: $45,587.04 ($39.03/share) KDNY Stock Analysis - Frequently Asked Questions Should I buy or sell Chinook Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares. View KDNY analyst ratings or view top-rated stocks. What is Chinook Therapeutics' stock price target for 2024? 2 brokerages have issued twelve-month price targets for Chinook Therapeutics' shares. Their KDNY share price targets range from $40.00 to $42.00. On average, they expect the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 1.5% from the stock's current price. View analysts price targets for KDNY or view top-rated stocks among Wall Street analysts. How were Chinook Therapeutics' earnings last quarter? Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.03. The firm earned $1.83 million during the quarter, compared to analysts' expectations of $0.14 million. Chinook Therapeutics had a negative net margin of 4,199.93% and a negative trailing twelve-month return on equity of 58.28%. Chinook Therapeutics's revenue for the quarter was down 32.2% compared to the same quarter last year. What other stocks do shareholders of Chinook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR). This page (NASDAQ:KDNY) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chinook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chinook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.